Although the use of IDO/TDO inhibitors by themselves has not been conclusive in clinical trials, their combination with immune checkpoint inhibitors has shown some effectiveness, which demonstrates the relevance of this pathway in the modulation of the anti-tumor immune system. This evidence concerns the gene IDO1 and neoplasm.